(Q71607051)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

title

Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

A A Vandenbark

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

Y K Chou

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

R Whitham

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

M Mass

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

A Buenafe

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

D Liefeld

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

D Kavanagh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

S Cooper

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

G A Hashim

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

H Offner

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

publication date

1 October 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

page(s)

1109-1115

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

Idiotypic networks and other preconceived ideas

19 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Autoimmunity, microbial immunity and the immunological homunculus

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Implications of a Fab-like structure for the T-cell receptor

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

T-cell antigen receptor genes and T-cell recognition

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

T cell receptor peptides in treatment of autoimmune disease: rationale and potential

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

The V-region disease hypothesis: evidence from autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Studies of V beta 8 T cell receptor peptide treatment in experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

The involvement of T cell receptor peptide-specific regulatory CD4+ T cells in recovery from antigen-induced autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

CDR1 T-cell receptor beta-chain peptide induces major histocompatibility complex class II-restricted T-T cell interactions.

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

T cell receptor peptide therapy for autoimmune encephalomyelitis: stronger immunization is necessary for effective vaccination

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Vaccination with T cell receptor peptides primes anti-receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Preferential T-cell receptor beta-chain variable gene use in myelin basic protein-reactive T-cell clones from patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Selection for T-cell receptor Vβ–Dβ–Jβ gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Characterization of T‐Cell Receptor Vβ Usage in the Brain of a Subject with Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Restricted T-cell receptor V beta gene usage by myelin basic protein-specific T-cell clones in multiple sclerosis: predominant genes vary in individuals

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

TCR peptide therapy decreases the frequency of encephalitogenic T cells in the periphery and the central nervous system

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

T-cell receptor peptide immunization leads to enhanced and chronic experimental allergic encephalomyelitis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

MHC-restriction, cytokine profile, and immunoregulatory effects of human T cells specific for TCR V beta CDR2 peptides: comparison with myelin basic protein-specific T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Self tolerance to T cell receptor V beta sequences

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

The specificity and orientation of a TCR to its peptide-MHC class II ligands

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

T helper 1 (Th1) functional phenotype of human myelin basic protein-specific T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

T cells responsive to myelin basic protein in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Episodic changes in T‐cell frequencies to myelin basic protein in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

MHC-Restricted Depletion of Human Myelin Basic Protein-Reactive T Cells by T Cell Vaccination

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Regulation of the development of distinct subsets of CD4+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Interleukin-10 prevents experimental allergic encephalomyelitis in rats.

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Enzymatic and nonenzymatic degradation of myelin basic protein

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Rapid typing of DNA sequence polymorphism at the HLA-DRB1 locus using the polymerase chain reaction and nonradioactive oligonucleotide probes

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

FURTHER NOTES ON DISABILITY EVALUATION IN MULTIPLE SCLEROSIS, WITH SCALE MODIFICATIONS

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNM1096-1109

7 January 2021

Identifiers

DOI

10.1038/NM1096-1109

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8837609%20AND%20SRC:MED&resulttype=core&format=json

19 October 2019

1 reference